GlassScriptPhysician profile
Ira Daniel Harber
NPI 1922539071
$7,088.28
in general payments reported to CMS, 2019-2025
29 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $26.24 · 2021: $1,129 · 2022: $1,023 · 2023: $1,156 · 2024: $1,375 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,010 · Education: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,010.25 |
| Education | $645.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,586.54 | 2021-2025 | |
| Abbvie INC. | $1,293.54 | 2021-2025 | |
| Janssen Biotech, INC. | $1,061.63 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $569.22 | 2022-2025 | Ilumya, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $356.22 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $353.86 | 2019-2025 | Dupixent |
| Pfizer INC. | $206.59 | 2019-2024 | |
| Ucb, INC. | $196.52 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $182.25 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $158.26 | 2025 | |
| Mallinckrodt Hospital Products INC. | $138.04 | 2023-2025 | Acthar |
| Leo Pharma INC. | $132.44 | 2021-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $129.78 | 2025 | Tremfya |
| Amgen INC. | $127.63 | 2023-2025 | Otezla, Otezla |
| Organogenesis INC. | $117.68 | 2023 | Puraply |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Incyte Corporation | $59.98 | 2022 | |
| Kerecis Limited | $48.86 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vyne Pharmaceuticals INC. | $37.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.05 | 2023-2024 | Spevigo |
| Celgene Corporation | $31.81 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $29.12 | 2019-2021 | |
| Integra Lifesciences Corporation | $24.59 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Avanir Pharmaceuticals, INC. | $21.78 | 2019 | |
| Galderma Laboratories, L.P. | $21.32 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $20.93 | 2022 | |
| Seagen INC. | $20.59 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.75 | 2024 | Jublia |
| Arcutis Biotherapeutics, INC. | $14.18 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Harber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.